Fabien Colaone

Fabien Colaone

Auto-generated profile, based on publicly available information

Fabien Colaone

Sirtex Medical Europe GmbH, Bonn, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in Future Oncology
Verified
Journal Article
Open access
SLSiu Hing Lo
Siu Hing Lo
RSRohini Sharma
Rohini Sharma
CCCharlotte E Costentin
Charlotte E Costentin
DADaniel Aggio
Daniel Aggio
SSSuki Shergill
Suki Shergill
ALAndrew J. Lloyd
Andrew J. Lloyd
The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living... Lay abstract This study aimed to understand patient preferences for characteristics of advanced hepatocellular carcinoma (HCC) treatments. A total of 150 people with HCC in Europe were presented a ...

12 March 2022 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
IAIon Agirrezabal
Ion Agirrezabal
VBVictoria K. Brennan
Victoria K. Brennan
FCFabien Colaone
Fabien Colaone
SSSuki Shergill
Suki Shergill
HPHelena Pereira
Helena Pereira
Valérie VilgrainValérie Vilgrain
Valérie Vilgrain
Introduction Given the relatively short life expectancy of patients with hepatocellular carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This analysis aimed to compare time to deterioration (TTD) in QOL with transarterial radioembolization (TARE) and atezolizumab–bevacizumab, as well as sorafenib, in advanced and unresectable HCC. Methods Patient-level data from SARAH (TARE using SIR-Spheres® Y-90 resin microspheres [SIR-Spheres] versus sorafenib) and aggregate data from IMbrave150 (atezolizumab–bevacizumab versus sorafenib) randomized controlled trials were used to conduct an anchored matching-adjusted indirect comparison (MAIC). Patients with a Child–Pugh score B in SARAH were excluded to align with exclusion criteria in IMbrave150. To identify potential effect modifiers for adjustment, the literature was searched and multivariate Cox proportional hazards models were implemented using SARAH data. Patients from SARAH were then weighted to balance with baseline characteristics from IMbrave150. Median TTD in QOL and hazard ratios (HRs) were calculated. Results Four potential effect modifiers were identified and used for adjustment: cause of disease (viral/non-viral), macrovascular invasion, Eastern Cooperative Oncology Group performance score, and alpha-fetoprotein level. The MAIC included 217 patients from SARAH (TARE = 94; sorafenib = 123). Median TTD in QOL was 11.23 and 8.64 months for atezolizumab–bevacizumab and TARE, respectively (HR = 1.06; 95% confidence interval [CI] 0.75–1.50; p = 0.725). A sensitivity analysis was conducted adjusting for cause of disease defined as hepatitis B/hepatitis C/non-viral: median TTD in QOL was higher for TARE compared with atezolizumab–bevacizumab (19.88 vs 11.23 months; HR = 0.66; 95% CI 0.36–1.19; p = 0.163). Sorafenib resulted in the shortest TTD in QOL, with statistically significant differences in both base case and sensitivity analyses. Conclusion TARE using SIR-Spheres may achieve similar TTD in QOL compared with atezolizumab–bevacizumab, as the analyses found no statistically significant differences between these two interventions. Both TARE using SIR-Spheres and atezolizumab–bevacizumab seem to be more efficacious than sorafenib in maintaining QOL.

23 November 2020 in Future Oncology
Verified
Journal Article
Open access
NMNoemi Muszbek
Noemi Muszbek
EREdit Remak
Edit Remak
RERachel Evans
Rachel Evans
VBVictoria K Brennan
Victoria K Brennan
FCFabien Colaone
Fabien Colaone
PRPaul J Ross
Paul J Ross
Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinom... Lay abstract Hepatocellular carcinoma is a complex disease, where in advanced stages there are limited treatment options. Among patients who are not eligible for liver transplant, removal of the tu...

1 September 2021 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
RPRichard F Pollock
Richard F Pollock
FCFabien Colaone
Fabien Colaone
SSSuki Shergill
Suki Shergill
VBVictoria K Brennan
Victoria K Brennan
IAIon Agirrezabal
Ion Agirrezabal
Background and Aims: Quality of life is among the most important considerations in the treatment of hepatocellular carcinoma (HCC), arguably second only to overall survival. Measuring and modeling patient quality of life is also crucial in the evaluation of the cost-effectiveness of health interventions. In the present study, we aimed to identify cost-utility analyses comparing selective internal radiation therapy (SIRT) with systemic therapy in patients with unresectable HCC and to compare the modeled incremental quality of life differences between the two therapies. Methods: A systematic literature review was conducted. PubMed, EMBASE, the Cochrane Library, and health technology assessment agency websites were searched to identify cost–utility studies of SIRT versus systemic therapies in the treatment of HCC. Key characteristics of the studies, modeled populations and incremental quality of life outcomes were extracted from the included studies. Results: The systematic literature review retrieved 1140 studies, of which four were ultimately included. Hand searches then identified two distinct analyses, and an updated version of one of the four studies identified initially. From these seven studies, 18 analyses were included. Analyses using data from the overall trial populations reported incremental quality-of-life estimates spanning − 0.09 to +0.28 quality-adjusted life years (QALYs), with that range expanding to − 0.09 to +0.60 QALYs when also considering post hoc sub-group analyses. Conclusion: The wide range of incremental QALYs, with substantial differences between overall trial populations and subgroups, illustrates the impact that the choice of target population may have on the relative quality of life outcomes of the compared interventions, which may in turn affect clinical decision-making. The small differences also highlight both the importance of reporting measures of dispersion around the findings, and the limitations of the incremental cost-effectiveness ratio (ICER) for assessing the relative cost-effectiveness of interventions that are predicted to result in similar quality-of-life outcomes.